Finally, by analyzing a public gene expression dataset, the same authors found that ovarian cancer patients with elevated levels of hCtr1 in their tumors, but not ATP7A and ATP7B, had more favorable outcomes after treatment with platinating drugs than those expressing low hCtr1 levels [91]. The gene discussed is SLC31A1; the disease is ovarian carcinoma.